Kiniksa PharmaceuticalsKNSA
KNSA
About: Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and mavrilimumab.
Employees: 315
0
Funds holding %
of 7,321 funds
–
Analysts bullish %
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
100% more funds holding in top 10
Funds holding in top 10: 1 [Q4 2024] → 2 (+1) [Q1 2025]
100% more first-time investments, than exits
New positions opened: 36 | Existing positions closed: 18
15% more capital invested
Capital invested by funds: $772M [Q4 2024] → $888M (+$116M) [Q1 2025]
10% more funds holding
Funds holding: 159 [Q4 2024] → 175 (+16) [Q1 2025]
1.23% more ownership
Funds ownership: 93.91% [Q4 2024] → 95.15% (+1.23%) [Q1 2025]
6% more call options, than puts
Call options by funds: $2.7M | Put options by funds: $2.55M
4% more repeat investments, than reductions
Existing positions increased: 59 | Existing positions reduced: 57
Research analyst outlook
2 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$42
45%
upside
Avg. target
$44
50%
upside
High target
$45
55%
upside
2 analyst ratings
2 positive
100%
0 neutral
0%
0 negative
0%
Wells Fargo Eva Fortea Verdejo | 45%upside $42 | Overweight Maintained | 9 Jul 2025 |
Jefferies Roger Song | 55%upside $45 | Buy Maintained | 29 Apr 2025 |
Financial journalist opinion
Based on 3 articles about KNSA published over the past 30 days
Positive
The Motley Fool
2 weeks ago
Kiniksa Pharmaceuticals: A 7.9 Score and Room for Growth
Explore the exciting world of Kiniksa Pharmaceuticals (KNSA 0.99%) with our expert analysts in this Motley Fool Scoreboard episode. Check out the video below to gain valuable insights into market trends and potential investment opportunities!
Positive
Zacks Investment Research
2 weeks ago
5 Biotech Stocks to Buy in 2025 Amid Uncertain Macroenvironment
New drug approvals and encouraging pipeline progress should maintain momentum in the Zacks Biomedical and Genetics industry despite the uncertain macroeconomic environment. A strong portfolio and solid pipeline progress position EXEL, VRNA, ALKS, KNSA and IMCR well in this volatile sector.
Positive
Investors Business Daily
2 weeks ago
Heart Drug Stock Rockets 20% On Sales, Boosts Outlook; Regeneron Pharma's Global Partnership Is Strong Tailwind
Biotech stock Kiniksa soared after first-quarter results on April 29. Shares are near a buy point of 28.15.
Positive
Seeking Alpha
1 month ago
Kiniksa Pharmaceuticals: Arcalyst Performs, KPL-387 Advancing Fast
Kiniksa Pharmaceuticals has delivered strong share price performance this year thanks to a strong start to the year for Arcalyst. Medicare redesign with improved patient affordability has boosted Arcalyst's sales and 2025 outlook. I expect a beat-and-raise 2025 with Arcalyst net sales reaching or exceeding $620 million.
Neutral
GlobeNewsWire
1 month ago
Kiniksa Pharmaceuticals Announces Trial Design of Planned Phase 2/3 Clinical Trial of KPL-387 in Recurrent Pericarditis
– KPL-387 Phase 2/3 trial on track to initiate in mid-2025; Phase 2 data expected in 2H 2026 – – KPL-387 Phase 1 single ascending dose data support profile for monthly dosing – – Presentation and webcast at Jefferies 2025 Global Healthcare Conference scheduled for 12:50 pm ET today–
Neutral
GlobeNewsWire
1 month ago
Kiniksa Pharmaceuticals to Present at Upcoming Investor Conferences
LONDON, May 29, 2025 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) today announced that management will present at the following investor conferences in June:
Positive
Seeking Alpha
2 months ago
Kiniksa Pharmaceuticals: Making Steady Progress
Kiniksa Pharmaceuticals posted strong Q1 results last week, beating expectations and raising 2025 ARCALYST net sales guidance to $590-$605 million, up from $560-$580 million. Analyst firms are optimistic, with firms like Goldman Sachs, Wedbush, and Jefferies assigning Buy ratings and price targets ranging from $32 to $45 on the shares. Kiniksa also has a solid balance sheet with nearly $270 million in cash and no long-term debt.
Neutral
GlobeNewsWire
2 months ago
Kiniksa Pharmaceuticals Announces GRAMMY® Award-Winning Country Star, Carly Pearce, Joins the Life DisRPted™ Campaign, Adding to Voices Advocating for Awareness of Recurrent Pericarditis
– Pearce joins NHL Hall-of-Famer, Henrik Lundqvist, to educate patients and caregivers about the importance of accurate and early diagnosis of recurrent pericarditis, a chronic autoinflammatory disease of the heart that is often underdiagnosed or misdiagnosed –
Neutral
Seeking Alpha
2 months ago
Kiniksa Pharmaceuticals International, plc (KNSA) Q1 2025 Earnings Call Transcript
Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA ) Q1 2025 Results Conference Call April 29, 2025 8:30 AM ET Company Participants Jonathan Kirshenbaum - Investor Relations Sanj Patel - Chairman & Chief Executive Officer Ross Moat - Chief Commercial Officer Mark Ragosa - Chief Financial Officer John Paolini - Chief Medical Officer Conference Call Participants Mary Kate - Citi Roger Song - Jefferies Eva Fortea-Verdejo - Wells Fargo Anupam Rama - JPMorgan David Nierengarten - Wedbush Operator Good day, and thank you for standing by. Welcome to the Kiniksa Pharmaceuticals First Quarter 2025 Earnings Conference Call.
Positive
Zacks Investment Research
2 months ago
Kiniksa Pharmaceuticals, Ltd. (KNSA) Tops Q1 Earnings and Revenue Estimates
Kiniksa Pharmaceuticals, Ltd. (KNSA) came out with quarterly earnings of $0.11 per share, beating the Zacks Consensus Estimate of $0.02 per share.
Charts implemented using Lightweight Charts™